Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immune-checkpoint inhibitors

被引：373

作者：

Schalper, Kurt A. ^{[1
]}

Carleton, Michael ^{[2
]}

Zhou, Ming ^{[3
]}

Chen, Tian ^{[3
]}

Feng, Ye ^{[3
]}

Huang, Shu-Pang ^{[3
]}

Walsh, Alice M. ^{[4
]}

Baxi, Vipul ^{[4
]}

Pandya, Dimple ^{[5
]}

Baradet, Timothy ^{[2
]}

Locke, Darren ^{[2
]}

Wu, Qiuyan ^{[5
]}

Reilly, Timothy P. ^{[5
]}

Phillips, Penny ^{[2
]}

Nagineni, Venkata ^{[1
]}

Gianino, Nicole ^{[1
]}

Gu, Jianlei ^{[6
]}

Zhao, Hongyu ^{[6
]}

Luis Perez-Gracia, Jose ^{[7
,8
]}

Sanmamed, Miguel F. ^{[7
,8
,9
,10
]}

Melero, Ignacio ^{[7
,8
,10
]}

机构：

[1] Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA

[2] Bristol Myers Squibb, Dept Translat Med, Princeton, NJ USA

[3] Bristol Myers Squibb, Dept Global Biometr Sci, Princeton, NJ USA

[4] Bristol Myers Squibb, Dept Translat Bioinformat, Princeton, NJ USA

[5] Bristol Myers Squibb, Dept Res & Early Dev, Princeton, NJ USA

[6] Yale Univ, Sch Publ Hlth, Dept Biostat, New Haven, CT USA

[7] Clin Univ Navarra, Oncol Dept, Pamplona, Spain

[8] Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

[9] Yale Univ, Sch Med, Dept Immunobiol, New Haven, CT USA

[10] Univ Navarra, Ctr Invest Med Aplicada CIMA, Dept Immunol & Immunotherapy, Pamplona, Spain

来源：

NATURE MEDICINE | 2020年 / 26卷 / 05期

基金：

欧盟地平线“2020”;

关键词：

SUPPRESSOR-CELLS; NIVOLUMAB; PD-1; IPILIMUMAB; DOCETAXEL;

D O I：

10.1038/s41591-020-0856-x

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Serum interleukin-8 (IL-8) levels and tumor neutrophil infiltration are associated with worse prognosis in advanced cancers. Here, using a large-scale retrospective analysis, we show that elevated baseline serum IL-8 levels are associated with poor outcome in patients (n = 1,344) with advanced cancers treated with nivolumab and/or ipilimumab, everolimus or docetaxel in phase 3 clinical trials, revealing the importance of assessing serum IL-8 levels in identifying unfavorable tumor immunobiology and as an independent biomarker in patients receiving immune-checkpoint inhibitors.

引用

页码：688 / +

页数：16

共 33 条

[1] Tumor-Produced Interleukin-8 Attracts Human Myeloid-Derived Suppressor Cells and Elicits Extrusion of Neutrophil Extracellular Traps (NETs)
Alfaro, Carlos
Teijeira, Alvaro
Onate, Carmen
Perez, Guiomar
Sanmamed, Miguel F.
Pilar Andueza, Maria
Alignani, Diego
Labiano, Sara
Azpilikueta, Arantza
Rodriguez-Paulete, Alfonso
Garasa, Saray
Fusco, Juan P.
Aznar, Angela
Inoges, Susana
De Pizzol, Maria
Allegretti, Marcello
Medina-Echeverz, Jose
Berraondo, Pedro
Perez-Gracia, Jose L.
Melero, Ignacio
[J]. CLINICAL CANCER RESEARCH, 2016, 22 (15) : 3924 - 3936
[2] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Ayers, Mark
Lunceford, Jared
Nebozhyn, Michael
Murphy, Erin
Loboda, Andrey
Kaufman, David R.
Albright, Andrew
Cheng, Jonathan D.
Kang, S. Peter
Shankaran, Veena
Piha-Paul, Sarina A.
Yearley, Jennifer
Seiwert, Tanguy Y.
Ribas, Antoni
McClanahan, Terrill K.
[J]. JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) : 2930 - 2940
[3] NEUTROPHIL-ACTIVATING PEPTIDE-1 INTERLEUKIN-8, A NOVEL CYTOKINE THAT ACTIVATES NEUTROPHILS
BAGGIOLINI, M
WALZ, A
KUNKEL, SL
[J]. JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (04) : 1045 - 1049
[4] CXCL8-the first chemokine
Baggiolini, Marco
[J]. FRONTIERS IN IMMUNOLOGY, 2015, 6
[5] Phase I trial of HuMax-IL8 (BMS-986253), an anti-IL-8 monoclonal antibody, in patients with metastatic or unresectable solid tumors
Bilusic, Marijo
Heery, Christopher R.
Collins, Julie M.
Donahue, Renee N.
Palena, Claudia
Madan, Ravi A.
Karzai, Fatima
Marte, Jennifer L.
Strauss, Julius
Gatti-Mays, Margaret E.
Schlom, Jeffrey
Gulley, James L.
[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
[6] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
Borghaei, H.
Paz-Ares, L.
Horn, L.
Spigel, D. R.
Steins, M.
Ready, N. E.
Chow, L. Q.
Vokes, E. E.
Felip, E.
Holgado, E.
Barlesi, F.
Kohlhaeufl, M.
Arrieta, O.
Burgio, M. A.
Fayette, J.
Lena, H.
Poddubskaya, E.
Gerber, D. E.
Gettinger, S. N.
Rudin, C. M.
Rizvi, N.
Crino, L.
Blumenschein, G. R.
Antonia, S. J.
Dorange, C.
Harbison, C. T.
Finckenstein, F. Graf
Brahmer, J. R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) : 1627 - 1639
[7] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer
Brahmer, Julie
Reckamp, Karen L.
Baas, Paul
Crino, Lucio
Eberhardt, Wilfried E. E.
Poddubskaya, Elena
Antonia, Scott
Pluzanski, Adam
Vokes, Everett E.
Holgado, Esther
Waterhouse, David
Ready, Neal
Gainor, Justin
Aren Frontera, Osvaldo
Havel, Libor
Steins, Martin
Garassino, Marina C.
Aerts, Joachim G.
Domine, Manuel
Paz-Ares, Luis
Reck, Martin
Baudelet, Christine
Harbison, Christopher T.
Lestini, Brian
Spigel, David R.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) : 123 - 135
[8] CARLETON M, 2018, J CLIN ONCOL S, V36
[9] Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Chalmers, Zachary R.
Connelly, Caitlin F.
Fabrizio, David
Gay, Laurie
Ali, Siraj M.
Ennis, Riley
Schrock, Alexa
Campbell, Brittany
Shlien, Adam
Chmielecki, Juliann
Huang, Franklin
He, Yuting
Sun, James
Tabori, Uri
Kennedy, Mark
Lieber, Daniel S.
Roels, Steven
White, Jared
Otto, Geoffrey A.
Ross, Jeffrey S.
Garraway, Levi
Miller, Vincent A.
Stephens, Phillip J.
Frampton, Garrett M.
[J]. GENOME MEDICINE, 2017, 9
[10] Neutrophils in cancer: neutral no more
Coffelt, Seth B.
Wellenstein, Max D.
de Visser, Karin E.
[J]. NATURE REVIEWS CANCER, 2016, 16 (07) : 431 - 446

← 1 2 3 4 →